Table 4 Creatinine concentrations, fluid balance, renal replacement therapy, and mortality rates in patients with transient, prolonged, and permanent oliguria
Non-oliguric on admission n = 6242 | Oliguria during ICU stay, n = 1349 | p value (across groups) | |||
|---|---|---|---|---|---|
Transient n = 390 (28.9%) | Prolonged n = 141 (10.5%) | Permanent n = 818 (60.6%) | |||
SAPS II score, mean ± SD | 37.9 ± 15.1 | 47.1 ± 16.7£ | 54.4 ± 17*,£ | 49.7 ± 18.8$,£ | < 0.001 |
Creatinine, highest concentration (mg/dl), median [IQR] | 0.9 [0.7–1.3] | 1.2 [0.8–2.1]£ | 1.6 [1.1–3.4]*,£ | 1.5 [0.9–2.8]*,£ | < 0.001 |
Daily fluid balancea, ml, median [IQR] | 3.3 [−612–605.7] | 49.9 [− 521–650] | 105.0 [− 541.3–780.1] | 308.9 [− 171.5–1123.7]*,$,£ | < 0.001 |
RRT at admission, n (%) | 97 (1.6) | 22 (5.6)£ | 31 (22)*,£ | 121 (14.8)*,£ | < 0.001 |
RRT during ICU stay, n (%) | 407 (6.5) | 48 (12.3)£ | 63 (44.7)*,£ | 273 (33.4)*,$,£ | < 0.001 |
ICU mortality, n (%) | 700 (11.5) | 27 (7.1)£ | 15 (10.9) | 232 (28.9)*,$,£ | < 0.001 |
In non RRT patients, n (%) | 580 (10.2) | 22 (6.6) | 8 (10.7) | 102 (19.1)*,£ | < 0.001 |
In RRT patients, n (%) | 120 (29.9) | 5 (10.9)£ | 7 (11.3)£ | 130 (48.3)*,$,£ | < 0.001 |
End-of-life decision, n (%) | 728 (11.7) | 47 (12.1) | 12 (8.5) | 163 (19.9)*,$,£ | < 0.001 |
In non RRT patients, n (%) | 650 (11.1) | 43 (12.6) | 8 (10.3) | 86 (15.8)£ | 0.012 |
In RRT patients, n (%) | 78 (19.2) | 4 (8.3) | 4 (6.3) | 77 (28.2)*,$,£ | < 0.001 |
Hospital mortality, n (%) | 983 (16.7) | 53 (14.7) | 33 (24.8)* | 296 (37.7)*,$,£ | < 0.001 |